Navigation Links
Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
Date:5/15/2008

had the option to continue on the trial for three more months per their prior randomized arm; for those participants, a third and final broncoscopy was conducted at six months.

"In patients who had high risk features such as smoking, especially in the current smokers, we were able to see that a higher dose of Celebrex could decrease the proliferation marker KI-67 in these patients, as seen through their bronchial epithelium," said Kim. "We are encouraged that we have a drug like Celebrex that decreases the expression of this proliferation marker."

These findings are also significant in that the study shows that serial broncoscopies are feasible, explained Kim. "Although CT scanning and other imaging techniques are important, for lung cancer, it may be vital to examine actual tissue to see what the markers are doing in the actual epithelium of the lung so as to best understand if an individual has a higher or lower risk of developing lung cancer."

Celebrex is in a class of medications known as nonsteroidal anti-inflammatory drugs (NSAIDs), like aspirin or ibuprofen, which work by blocking chemical enzymes that cause inflammation.

The COX-2 enzyme inside cancer cells is thought to control the synthesis of prostaglandins, which are substances believed to trigger cancer cell growth. Researchers believe that prostaglandins promote the growth of new blood vessels to feed tumors, and also protect new cancers from destruction by the body's immune system. Blocking the COX-2 enzyme may reduce the amount of prostaglandin available to cancer cells and thus repress tumor growth, says Kim.

In December 2004, M. D. Anderson voluntarily suspended the trial at the request of Pfizer and the National Cancer Institute, the funding source for the study, until further data on the drug's risk for cardiac toxicities, specifically heart attacks and strokes, could be investigated. Months later, advisors to the FDA recommended that Celebrex contin
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Celebrex, Naproxen Wont Prevent Mental Decline
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex-Lipitor combo may halt prostate cancer
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
6. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
7. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
8. Research shows HPV testing offers women protection for twice as long as smear testing
9. Study shows that prostate cancer increases the risk of bone fracture
10. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
11. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... York, NY (PRWEB) November 27, 2014 The ... to offering stylish, comfortable and high functioning compression socks, are ... The newly-released socks use an innovative Gradient Pressure (TM) knitting ... oxygenated blood. , VIM & VIGR’s commitment to adding flair ... of as just functional recently caught the eye of a ...
(Date:11/27/2014)... 27, 2014 Now that Thanksgiving is ... officially launched, Emassagechair.com has announced its eagerly ... Event. , Negotiating on behalf of their customers, ... chair brands, Emassagechair.com has generated significant buzz in the ... biggest discounts yet. , Shoppers are excited for significant ...
(Date:11/27/2014)... CA (PRWEB) November 27, 2014 Two ... dental implants procedure will help one person with ... , Dr. Saj Jivraj and Dr. Mamaly Reshad of ... Hills, Calif., have launched a website devoted to helping ... section of the website would be devoted to helping ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... by researchers at Columbia University Medical Center to analyze ... to cancer treatment, //it has been found that nearly ... More specifically, stage III colon cancer patients who were ... months, were found to stop their treatment before completion. ...
... workers frequently report sick due to respiratory problems, and ... develop// occupational asthma every year. Prolonged exposure to dust ... ,Alveolitus or 'occupational asthma’ is triggered by constant ... of the lung. It is said that the ...
... Mali in West Africa, which is said to be naturally ... according to scientists//. , ,A team including researchers from ... US-based institutes said they have also identified a gene that ... to infection by the parasite, reported the online edition of ...
... of Celebrex was $3.3 billion worldwide. But after widespread concerns ... But 16 months later the has returned to the consumer ... which plunged last year during the ad moratorium. Now the ... ingredients that could boost it sales. Each ad includes ...
... Pacific Northwest National Laboratory, scientists have developed a new ... levels. They have taken a polymer (protein) and layered ... capacity. ,This configuration can accommodate a wide ... detection, said Yuehe Lin, who led the research at ...
... late 1950s was later discarded as a stunt. However recent ... the one who pioneered this in 1957. He claimed that ... a second actually bought the advertised product. He had tested ... his results in the tests they had conducted. Vicary later ...
Cached Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Polymer Molecule Layered On Carb Molecule to Increase Sensitivity 2
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
(Date:11/26/2014)... Nov. 26, 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced ... to raise approximately $3.3 million at a price of ... one institutional healthcare focused investor. Each unit consists of one ... share purchase warrant. Each whole warrant entitles the holder ... $0.30 for a period of five years from closing.  ...
(Date:11/26/2014)... , Nov. 26, 2014  Cohen, Placitella ... behalf of investors who purchased Nymox Pharmaceutical Corporation ... during the period from January 31, 2011 through ... whether Nymox and certain of its officers and ... in violation of Sections 10(b) and 20(a) of ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: